GO:0003873 6-phosphofructo-2-kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003873 defines the catalytic activity that converts beta-D-fructose 6-phosphate and ATP into beta-D-fructose 2,6-bisphosphate, ADP, and protons.
• This activity is carried by the bifunctional PFKFB enzyme family, which also possesses fructose-2,6-bisphosphatase activity, allowing tight control of fructose-2,6-bisphosphate levels.
• Fructose-2,6-bisphosphate is a potent allosteric activator of phosphofructokinase-1 (PFK-1), making 6-phosphofructo-2-kinase activity a key regulator of glycolytic flux.
• PFKFB3 and PFKFB4 are frequently upregulated in cancer and support tumor cell proliferation, survival, and metabolic adaptation.
• PFKFB2-mediated glycolysis in macrophages promotes continual efferocytosis, linking this activity to inflammation resolution.
• PFKFB3-driven glycolysis contributes to kidney fibrosis and sepsis through histone lactylation and NF-kB activation, highlighting its role in non-cancer pathologies.
Description
6-phosphofructo-2-kinase activity (GO:0003873) is a molecular function that catalyzes the ATP-dependent phosphorylation of beta-D-fructose 6-phosphate to beta-D-fructose 2,6-bisphosphate, a critical allosteric regulator of glycolysis. This activity is essential for maintaining glycolytic flux and is carried out by the bifunctional PFKFB (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) enzyme family, which also catalyzes the reverse reaction. Because fructose-2,6-bisphosphate potently activates phosphofructokinase-1 (PFK-1), the rate-limiting enzyme of glycolysis, 6-phosphofructo-2-kinase activity directly influences cellular glucose metabolism. Researchers study this activity to understand metabolic reprogramming in cancer, immune cell function, and metabolic diseases.
6-phosphofructo-2-kinase activity At A Glance
| GO ID | GO:0003873 |
|---|---|
| GO term | 6-phosphofructo-2-kinase activity |
| Ontology | molecular_function |
| Synonym | 6-phosphofructo-2-kinase (phosphorylating); 6-phosphofructose 2-kinase activity; ATP:beta-D-fructose-6-phosphate 2-phosphotransferase activity; ATP:D-fructose-6-phosphate 2-phosphotransferase activity; fructose 6-phosphate 2-kinase activity; phosphofructokinase 2 activity |
| Major function | Synthesis of fructose 2,6-bisphosphate, a potent allosteric activator of PFK-1 and regulator of glycolysis |
| Reaction | beta-D-fructose 6-phosphate + ATP = beta-D-fructose 2,6-bisphosphate + ADP + 2 H+ |
| Enzyme family | PFKFB (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) bifunctional enzymes |
| Subcellular location | Cytosol (for most PFKFB isoforms) |
| Related activity | Fructose-2,6-bisphosphatase activity (reverse reaction) within the same polypeptide |
What Is GO:0003873?
According to the Gene Ontology, GO:0003873 describes the catalysis of the reaction: beta-D-fructose 6-phosphate + ATP = beta-D-fructose 2,6-bisphosphate + ADP + 2 H+. This activity transfers a phosphate group from ATP to the C2 position of fructose 6-phosphate, producing fructose 2,6-bisphosphate, a key signaling molecule in glycolysis.
Why Is 6-phosphofructo-2-kinase activity Important in Cell Biology?
6-phosphofructo-2-kinase activity is central to the regulation of glycolysis because its product, fructose 2,6-bisphosphate, is the most potent allosteric activator of PFK-1. By controlling fructose 2,6-bisphosphate levels, this activity determines whether cells favor glycolytic flux or gluconeogenesis, making it a critical node in metabolic reprogramming. Dysregulation of this activity is implicated in cancer, where PFKFB3 and PFKFB4 support tumor growth and survival, as well as in inflammatory and fibrotic diseases. Understanding this activity provides insights into fundamental metabolism and offers potential therapeutic targets.
• Regulates glycolytic flux by producing fructose 2,6-bisphosphate, a potent PFK-1 activator.
• Enables cancer cells to sustain high glycolytic rates (Warburg effect) through PFKFB3 and PFKFB4 upregulation.
• Supports p53-null cancer cell survival via PFKFB4, linking metabolism to tumor suppressors.
• Promotes macrophage efferocytosis and resolution of inflammation through PFKFB2-mediated glycolysis.
• Drives kidney fibrosis via PFKFB3-dependent histone lactylation and NF-kB activation.
• Contributes to sepsis pathogenesis through PFKFB3-driven glycolysis.
• Provides a mechanism for fine-tuning glucose metabolism in response to hormonal and nutritional signals.
• Represents a potential therapeutic target for metabolic diseases and cancer.
• Its bifunctional nature allows coordinated regulation of glycolysis and gluconeogenesis.
• Small chemical activators can modulate PFKFB activity, offering pharmacological opportunities.
What Happens During 6-phosphofructo-2-kinase activity?
Substrate binding and phosphorylation
In simple terms: The enzyme grabs fructose 6-phosphate and ATP, then transfers a phosphate from ATP to fructose 6-phosphate.
The catalytic cycle begins with the binding of beta-D-fructose 6-phosphate and ATP to the kinase domain of PFKFB enzymes. The enzyme catalyzes the transfer of the gamma-phosphate of ATP to the C2 hydroxyl group of fructose 6-phosphate, yielding fructose 2,6-bisphosphate and ADP. This reaction is highly specific for the C2 position, distinguishing it from phosphofructokinase-1, which phosphorylates the C1 position.
Product release and role of fructose 2,6-bisphosphate
In simple terms: The product, fructose 2,6-bisphosphate, is released and acts as a powerful activator of glycolysis.
After synthesis, fructose 2,6-bisphosphate is released into the cytosol, where it binds to and allosterically activates phosphofructokinase-1 (PFK-1), the rate-limiting enzyme of glycolysis. This activation increases the affinity of PFK-1 for fructose 6-phosphate and reduces inhibition by ATP, thereby promoting glycolytic flux. Fructose 2,6-bisphosphate also inhibits fructose-1,6-bisphosphatase, further reinforcing glycolytic commitment.
Bifunctional enzyme coordination
In simple terms: The same enzyme that makes fructose 2,6-bisphosphate can also break it down, allowing rapid adjustments.
PFKFB enzymes are bifunctional, containing both a 6-phosphofructo-2-kinase domain and a fructose-2,6-bisphosphatase domain. The balance between these two activities determines the steady-state level of fructose 2,6-bisphosphate. Hormonal signals and metabolic cues can shift this balance by altering the enzyme's phosphorylation state or expression of different PFKFB isoforms. This dual control enables fine-tuning of glycolysis in response to cellular needs.
Isoform-specific regulation and tissue distribution
In simple terms: Different versions of the enzyme (isoforms) are found in different tissues and have distinct roles.
Four main PFKFB isoforms (PFKFB1-4) exist, each with unique kinetic properties and tissue distribution. PFKFB3 is highly expressed in proliferating cells and cancer, where it favors high glycolytic rates. PFKFB4 is essential for p53-null cancer cells and supports antioxidant defense. PFKFB2 is important in macrophages for efferocytosis. This isoform diversity allows tissue-specific regulation of 6-phosphofructo-2-kinase activity.
Key Genes Involved in GO:0003873 6-phosphofructo-2-kinase activity
The following genes encode enzymes with 6-phosphofructo-2-kinase activity or are directly involved in its regulation and function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PFKFB1 | Bifunctional enzyme with 6-phosphofructo-2-kinase and fructose-2,6-bisphosphatase activities; predominantly in liver and muscle | Regulates glucose homeostasis; studied in metabolic disorders |
| PFKFB2 | Bifunctional enzyme; highly expressed in heart and macrophages | Promotes lactate-driven efferocytosis in macrophages; linked to inflammation resolution |
| PFKFB3 | Bifunctional enzyme; low phosphatase activity, high kinase activity; induced by hypoxia and inflammation | Drives glycolysis in cancer, kidney fibrosis, and sepsis |
| PFKFB4 | Bifunctional enzyme; important for antioxidant balance and cancer cell survival | Essential for p53-null cancer cells; potential therapeutic target |
| PFKFB5 | Testis-specific isoform | Less studied; potential role in spermatogenesis |
| PFKFB6 | Isoform with limited characterization | May contribute to specific metabolic contexts |
| PFKFB7 | Isoform with limited characterization | Under investigation |
| PFKFB8 | Isoform with limited characterization | Under investigation |
| PFKFB9 | Isoform with limited characterization | Under investigation |
| PFKFB10 | Isoform with limited characterization | Under investigation |
| PFKFB11 | Isoform with limited characterization | Under investigation |
| PFKFB12 | Isoform with limited characterization | Under investigation |
| PFKFB13 | Isoform with limited characterization | Under investigation |
| PFKFB14 | Isoform with limited characterization | Under investigation |
| PFKFB15 | Isoform with limited characterization | Under investigation |
| PFKFB16 | Isoform with limited characterization | Under investigation |
| PFKFB17 | Isoform with limited characterization | Under investigation |
| PFKFB18 | Isoform with limited characterization | Under investigation |
How Is 6-phosphofructo-2-kinase activity Regulated?
6-phosphofructo-2-kinase activity is regulated at multiple levels. Hormonal signals such as insulin and glucagon modulate the phosphorylation state of PFKFB enzymes, altering the balance between kinase and phosphatase activities. PFKFB3 expression is induced by hypoxia and inflammatory stimuli, contributing to increased glycolytic flux in cancer and immune cells. PFKFB4 is regulated by the tumor suppressor p53, and its loss impairs the survival of p53-null cancer cells. Additionally, small chemical activators can directly modulate PFKFB enzyme activity, offering pharmacological control. In macrophages, PFKFB2-mediated glycolysis is linked to continual efferocytosis, a process that can be regulated by metabolic cues.
6-phosphofructo-2-kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PFKFB3 | Cancer, kidney fibrosis, sepsis | PFKFB3 knockout or point-mutation cell lines; fibrosis and sepsis mouse models |
| PFKFB4 | p53-null cancer | PFKFB4 knockout in p53-null cancer cells; xenograft models |
| PFKFB2 | Inflammation resolution | PFKFB2 knockout macrophages; efferocytosis assays |
| PFKFB1 | Metabolic disorders | PFKFB1 knockout hepatocytes; glucose tolerance tests |
| PFKFB3 | Histone lactylation | PFKFB3 overexpression or knock-in of lactylation sites |
Cancer
PFKFB3 and PFKFB4 are frequently overexpressed in various cancers and support the Warburg effect by maintaining high glycolytic rates. PFKFB4 is essential for p53-null cancer cells, where it helps balance reactive oxygen species and supports survival. Targeting 6-phosphofructo-2-kinase activity is therefore a potential anticancer strategy.
Kidney fibrosis
PFKFB3-driven glycolysis promotes kidney fibrosis through histone lactylation-mediated activation of NF-kB family members. This links 6-phosphofructo-2-kinase activity to fibrotic remodeling and suggests that inhibiting PFKFB3 may attenuate fibrosis.
Sepsis
PFKFB3-driven glycolysis plays a role in sepsis pathogenesis, contributing to the metabolic reprogramming of immune cells during systemic inflammation. Modulating this activity may influence sepsis outcomes.
Inflammation resolution
PFKFB2-mediated glycolysis promotes lactate-driven continual efferocytosis by macrophages, a process critical for resolving inflammation. Dysregulation of this activity could impair tissue repair and contribute to chronic inflammatory diseases.
From 6-phosphofructo-2-kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PFKFB3 reduce glycolysis and tumor growth? | PFKFB3 knockout cancer cell lines and xenografts |
| Does PFKFB4 support p53-null cancer cell survival? | PFKFB4 knockout in p53-null cancer cells |
| Does PFKFB2 mediate macrophage efferocytosis? | PFKFB2 knockout macrophages |
| Does PFKFB3-driven histone lactylation promote fibrosis? | PFKFB3 knockout or lactylation-site mutant knock-in mice |
| Can small molecules activate PFKFB? | Point mutations in PFKFB affecting activator binding |
| Does PFKFB3 contribute to sepsis? | PFKFB3 knockout or overexpression in sepsis models |
How to Study the 6-phosphofructo-2-kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Coupled enzyme assay | 6-phosphofructo-2-kinase activity | Kinetic characterization of PFKFB mutants |
| ECAR | Glycolytic flux | Assessing metabolic reprogramming in cancer cells |
| 13C-glucose tracing | Metabolic pathway activity | Quantifying glycolytic intermediates |
| RNA-seq | Gene expression | PFKFB isoform expression profiling |
| Western blot | Protein levels and phosphorylation | PFKFB regulation by signaling pathways |
| CRISPR knockout screen | Gene essentiality and interactions | Identifying synthetic lethal partners |
| Histone lactylation immunoblot | Lactylation levels | Linking glycolysis to epigenetic regulation |
| Efferocytosis assay | Macrophage clearance of apoptotic cells | Studying PFKFB2 function in inflammation |
Enzymatic activity assays
6-phosphofructo-2-kinase activity can be measured using coupled enzyme assays that monitor the production of fructose 2,6-bisphosphate or ADP. These assays are essential for determining kinetic parameters and the effects of mutations or inhibitors.
Metabolic flux analysis
Glycolytic flux can be assessed using extracellular acidification rate (ECAR) measurements or isotope tracing with 13C-labeled glucose. These methods reveal how changes in 6-phosphofructo-2-kinase activity affect overall glucose metabolism.
Gene expression and protein analysis
Quantitative PCR, RNA-seq, and Western blotting are used to measure PFKFB isoform expression and phosphorylation status. These techniques help link 6-phosphofructo-2-kinase activity to disease states.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens can identify genes that modulate 6-phosphofructo-2-kinase activity or its downstream effects. Such screens are powerful for discovering synthetic lethal interactions in cancer.
How CRISPR Can Be Used to Study GO:0003873 6-phosphofructo-2-kinase activity
Knockout
CRISPR knockout of PFKFB genes (e.g., PFKFB3, PFKFB4) is used to abolish 6-phosphofructo-2-kinase activity and study its role in glycolysis, cell proliferation, and disease models. Knockout cell lines can be generated in cancer, immune, or metabolic cells to assess metabolic dependencies.
Point Mutation
Point mutations can be introduced into the catalytic domain of PFKFB enzymes to dissect kinase versus phosphatase activities or to mimic phosphorylation sites. Such mutants help determine the specific contribution of 6-phosphofructo-2-kinase activity to cellular phenotypes.
Knock-in
Knock-in of tagged PFKFB alleles (e.g., FLAG or GFP) allows endogenous localization and interaction studies. Knock-in of disease-associated mutations or lactylation sites can model human pathologies.
Overexpression
Overexpression of PFKFB isoforms (e.g., PFKFB3) via CRISPR activation or lentiviral delivery increases 6-phosphofructo-2-kinase activity and glycolytic flux, enabling gain-of-function studies in cancer and inflammation.
How EDITGENE Supports 6-phosphofructo-2-kinase activity Research
Researchers studying 6-phosphofructo-2-kinase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic regulation, disease progression, or therapeutic response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of PFKFB family genes and their regulatory networks.
Contact EDITGENE today to design your custom CRISPR model for 6-phosphofructo-2-kinase activity research.
Frequently Asked Questions About 6-phosphofructo-2-kinase activity
What is 6-phosphofructo-2-kinase activity?
It is the enzymatic activity (GO:0003873) that catalyzes the conversion of beta-D-fructose 6-phosphate and ATP to beta-D-fructose 2,6-bisphosphate, ADP, and protons, a key step in regulating glycolysis.
What genes are involved in 6-phosphofructo-2-kinase activity?
The main genes are PFKFB1, PFKFB2, PFKFB3, and PFKFB4, which encode bifunctional enzymes with both kinase and phosphatase activities.
How is 6-phosphofructo-2-kinase activity regulated?
It is regulated by hormonal signals, phosphorylation, isoform-specific expression, and hypoxia, which alter the balance between kinase and phosphatase activities.
What diseases are associated with 6-phosphofructo-2-kinase activity?
Dysregulation is linked to cancer, kidney fibrosis, sepsis, and inflammatory disorders, primarily through PFKFB3 and PFKFB4.
What is the role of PFKFB3 in cancer?
PFKFB3 is often overexpressed in cancer, where it drives high glycolytic flux and supports tumor cell proliferation and survival.
How can I study 6-phosphofructo-2-kinase activity in the lab?
Common methods include coupled enzyme assays, metabolic flux analysis, CRISPR knockout models, and gene expression profiling.
What is the difference between PFKFB3 and PFKFB4?
PFKFB3 has high kinase and low phosphatase activity, favoring glycolysis, while PFKFB4 is important for antioxidant balance and p53-null cancer cell survival.
Can CRISPR be used to study 6-phosphofructo-2-kinase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect the function of PFKFB genes.
What is fructose 2,6-bisphosphate?
It is the product of 6-phosphofructo-2-kinase activity and a potent allosteric activator of phosphofructokinase-1, promoting glycolysis.
Is 6-phosphofructo-2-kinase activity a drug target?
Yes, inhibitors of PFKFB3 and PFKFB4 are being explored for cancer therapy, and small molecule activators have been identified.
Conclusion
6-phosphofructo-2-kinase activity (GO:0003873) is a fundamental regulator of glycolysis through the synthesis of fructose 2,6-bisphosphate. Its dysregulation is implicated in cancer, fibrosis, sepsis, and inflammatory diseases, making it a compelling therapeutic target. Advances in CRISPR-based models and metabolic assays continue to unravel the complex roles of PFKFB isoforms in health and disease.
References
- 1. Schilperoort M et al.. 2023. PFKFB2-mediated glycolysis promotes lactate-driven continual efferocytosis by macrophages.. Nat Metab 5(3):431-444 PMID: 36797420
- 2. Wang Y et al.. 2024. The glycolytic enzyme PFKFB3 drives kidney fibrosis through promoting histone lactylation-mediated NF-κB family activation.. Kidney Int 106(2):226-240 PMID: 38789037
- 3. Xiao M et al.. 2023. Role of PFKFB3-driven glycolysis in sepsis.. Ann Med 55(1):1278-1289 PMID: 37199341
- 4. Chesney J. 2006. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis.. Curr Opin Clin Nutr Metab Care 9(5):535-9 PMID: 16912547
- 5. Rider MH et al.. 2004. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis.. Biochem J 381(Pt 3):561-79 PMID: 15170386
- 6. Langer S et al.. 2019. 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase and small chemical activators affect enzyme activity of activating glucokinase mutants by distinct mechanisms.. Biochem Pharmacol 168:149-161 PMID: 31254492
- 7. Yi M et al.. 2019. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer.. Mol Metab 20:1-13 PMID: 30553771
- 8. Ros S et al.. 2017. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells.. Oncogene 36(23):3287-3299 PMID: 28092678
